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ORIGINAL ARTICLE
Background: Deterioration in health-related quality of life (HRQOL) 
is frequently observed after surgery for stage I non–small-cell lung 
cancer. As stereotactic ablative radiotherapy (SABR) can result in 
local control percentages exceeding 90%, we studied baseline and 
post-treatment HRQOL in SABR patients.
Methods: HRQOL data were collected prospectively using the 
European Organization for Research and Treatment of Cancer 
(EORTC) QLQ-C30 questionnaire in 382 consecutive patients 
treated with SABR. Patients were referred from 68 Dutch centers, 
with 86% judged unfit for surgery, and 14% declining surgery. An 
SABR dose of 60 Gy was delivered in three-, five-, or eight treatment 
fractions, depending on tumor diameter and location. HRQOL data 
were available for 382 patients at baseline (pre-SABR), and for 282, 
212, 144, 56, and 43 patients at 3, 6, 12, 18, and 24 months post-
SABR, respectively.
Results: Median survival was 40 months, with a 2-year survival 
of 66%. Local, regional, and distant failure percentages at 2 years 
were 6%, 13%, and 22%, respectively. Mean baseline global 
HRQOL and physical functioning scores were 62.9 ± 1.1 and 61.7 
± 1.1, respectively. Baseline symptom scores were highest for dys-
pnea (47.1 ± 1.7) and fatigue (37.4 ± 1.3). Except for a nonsig-
nificant decrease in 2 to 3 points per year in physical functioning, 
no statistically or clinically significant worsening of any of the 
HRQOL functioning or symptom scores at any follow-up time 
point was observed.
Conclusions: Patients referred for SABR have substantially worse 
baseline HRQOL scores than those reported in the surgical literature. 
Clinically relevant deteriorations in HRQOL subscale scores were 
not observed after SABR.
Key Words: Quality of life, Stage I lung cancer, Stereotactic ablative 
radiotherapy.
(J Thorac Oncol. 2012;7: 1148–1154)
Surgery is considered the standard of care for fit patients with stage I non–small-cell lung cancer (NSCLC). 
However, lung cancer is increasingly a disease of less fit 
patients with a median age of 70 years at diagnosis, with one 
in three patients aged 75 years or older at diagnosis.1 Several 
studies of surgically treated patients with early-stage lung 
cancer have reported compromised health-related quality of 
life (HRQOL) in the first 6 months postsurgery, with patients 
aged 70 years and more, and those with poorer pretreatment 
HRQOL, in particular, failing to show a return to baseline 
HRQOL levels.2–6
Prospective clinical studies of stereotactic ablative 
radiotherapy (SABR) in stage I NSCLC have reported 3-year 
local control percentages of 92% to 98%.7–9 Toxicity is uncom-
mon after SABR for peripheral tumors, and consists mainly 
of chest pain, rib fractures, and radiation pneumonitis, all of 
which have been reported in less than 5% of patients.10 The 
current experience with SABR has been primarily in elderly 
patients who are medically inoperable, and there are lim-
ited baseline and post-treatment HRQOL data available for 
this population. The diagnosis of stage I NSCLC is usually 
made in the absence of tumor-related symptoms, and poorer 
baseline HRQOL is mostly caused by comorbidities such as 
chronic obstructive pulmonary disease (COPD).11,12 As a con-
sequence, preservation of baseline HRQOL can be regarded 
as the optimal result of treatment for stage I NSCLC.
With the introduction of SABR at the VU University 
Medical Center (Amsterdam) in 2003, it became institutional 
policy to prospectively collect serial HRQOL data in all stage 
I NSCLC patients undergoing this treatment. Local medical 
ethical committee approval was obtained for collecting these 
HRQOL data as a standard part of treatment follow-up. In this 
article, we report the clinical outcomes, treatment toxicities, 
and HRQOL of patients who underwent SABR for stage I 
NSCLC.
MATERIALS AND METHODS
A prospective database containing baseline and fol-
low-up data of all patients treated with SABR for a stage I 
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NSCLC is maintained at our center. A cohort study was per-
formed in 382 consecutive patients treated between April 
2003 and November 2008, with available HRQOL data. 
Patients had been referred to the VU University Medical 
Center from 68 hospitals in the Netherlands. Before undergo-
ing SABR, all patients were discussed in a multidisciplinary 
oncology team, and were considered medically inoperable (n 
= 323; 86%) or had declined surgery (n = 59; 14%). The group 
consisted of 230 men (60%) and 152 women (40%), with a 
median age of 74 years. In general, patients had poor pretreat-
ment pulmonary function, with 72% classified as moderate, 
severe, or very severe COPD according to the global initiative 
for obstructive lung disease (GOLD) criteria.13 In this patient 
cohort, the incidence of comorbidity was substantial, with a 
mean-age–adjusted Charlson comorbidity index score of 6.9 
(range, 2–12).14
Details of the 408 tumors treated in these 382 patients are 
summarized in Table 1. Included were 255 T1 tumors (63%) 
and 153 T2 tumors (37%), with a maximum diameter between 
10 and 79 mm. Patient staging was performed according to 
American Joint Committee of Cancer v.6 using computed 
tomo graphy scans of the thorax and abdomen18 fluorode-
oxyglucose-positron emission tomography scans in all except 
three patients. Details of target volume delineation, the use of 
one of three risk-adapted fractionation schemes, all with a bio-
logically effective dose of 100 Gy
10 
or more and SABR delivery 
technique have been described in our previous report.9 In brief, 
patients with a peripheral tumor less than 3 cm (T1) that did not 
have broad contact with the thoracic wall were treated in three 
fractions of 20 Gy, whereas patients with T1 lesions abutting 
the thoracic wall and larger T2 lesions were treated with five 
fractions of 12 Gy. Lesions adjacent to the heart, hilus, medi-
astinum, plexus, or esophagus were treated in eight fractions 
of 7.5 Gy. Patients were routinely followed up at 3 months, 
6 months, 12 months, 18 months, and 24 months if their clini-
cal condition permitted this. Computed tomography scans were 
performed at each follow-up visit and 18 fluorodeoxyglucose- 
positron emission tomography scans were only obtained if 
clinically indicated. Both early and late toxicity were scored 
according to the Radiation Therapy Oncology Group (RTOG) 
toxicity grading system during follow-up visits, and by tel-
ephonic consultations.15
With the approval of the medical ethics committee, 
HRQOL data were collected routinely during follow-up vis-
its. HRQOL was assessed with the EORTC QLQ-C30 (ver-
sion 3.0).16 The QLQ-C30 consists of 30 questions that assess 
physical-, emotional-, role-, social-, and cognitive-functioning 
dimensions of HRQOL, and a range of symptoms (e.g., dys-
pnea, loss of appetite, fatigue, sleep disturbances, and pain). 
The questionnaire has been extensively tested and validated.17 
Global HRQOL is measured with two items in the QLQ-C30, 
one addressing overall health and the other overall HRQOL 
on a 7-point scale (1 indicating “very poor” to 7 indicating 
“excellent”). All other questions employ a 4-point scale (1, 
indicating “not at all” to 4, indicating “very much”). The time 
frame of the questions is the previous week. The questionnaire 
was completed by patients before the clinic visit and took 
approximately 10 to 15 minutes to complete.
Statistical Analysis
All scores on the EORTC QLQ-C30 were linearly trans-
formed to a 0 to 100 scale according to the EORTC guidelines. 
Higher scores on the functional HRQOL scales indicate bet-
ter functioning, whereas higher scores on the symptom scales 
indicate more severe symptoms. A 10-point difference on any 
of the HRQOL scales is generally considered to be a “moder-
ate” difference, which can be regarded as clinically meaning-
ful.18,19 Mean changes of more than 20 points are considered 
to be large effects.
The median follow-up duration was 23 months. 
Multilevel analyses were conducted to evaluate whether there 
was a statistically significant change in HRQOL scores over 
TABLE 1.  Baseline Characteristics (N = 382)
Sex
 Male 60.2% (n = 230)
 Female 39.8% (n = 152)
Median age 74 years (range, 47–91)
T-stage
 IA 60.2% (n = 230)
 IB 39.8% (n = 152)
Median-age–adjusted Charlson score 6.9 (range, 2–12)
Median-non-age–adjusted Charlson score 4.1 (range, 0–10)
History of prior lung cancer
 Yes 17.0% (n = 65)
 No 83.0% (n = 317)
Tumor location
 Peripheral 80.9% (n = 309)
 Central 17.8% (n = 68)
 Both 1.3% (n = 5)
Mean tumor diameter (range) 28 (range, 10–79 mm)
COPD GOLD class (N = 361)
 No COPD 15.8% (n = 57)
 GOLD 1 12.2% (n = 44)
 GOLD 2 36.8% (n = 133)
 GOLD 3 28.3% (n = 102)
 GOLD 4 6.9% (n = 25)
Performance status (WHO) (N = 380)
 0 11.1% (n = 42)
 1 52.9% (n = 201)
 2 31.8% (n = 121)
 3 4.2% (n = 16)
Median FEV1 (range) 1.46 liter (61% of 
predicted)
SABR indication
 Refusal of surgery 15.4% (n = 59)
 Medically inoperable 84.6% (n = 323)
Fractions SABR
 3 40.1% (n = 153)
 5 44.5% (n = 170)
 8 15.4% (n = 59)
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume 
in 1 second; GOLD, global initiative for obstructive lung disease; WHO, World Health 
Organization.
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time. Specifically, mixed-effects linear regression for lon-
gitudinal data was used, where two levels were defined: (1) 
repeated measures (HRQOL) treated as a continuous variable, 
and (2) patients. In those cases where the overall results were 
significant, paired Student’s t tests were employed to determine 
at which points in time (in comparison to baseline) HRQOL 
scores had changed significantly. Cox regression analysis was 
used to examine which clinical and HRQOL factors predicted 
overall survival (OS). The variables included in this latter anal-
ysis were baseline global HRQOL, physical functioning (PF), 
age, sex, performance score, comorbidity score, COPD clas-
sification, and tumor stage. To evaluate the impact of missing 
data on PF scores, we calculated effect sizes (Cohen’s d statis-
tic) on the basis of difference in mean baseline scores between 
those patients with and without HRQOL data at each of the 
follow-up assessments, divided by the pooled baseline SD. 
Effect sizes of 0.2 are considered small, 0.5 moderate, and 0.8 
or greater as large.20 The multilevel analyses were carried out 
using the statistical software package MLwin (version 2.02, 
University of Bristol, Bristol, United Kingdom). All other 
statistical analyses were performed using the SPSS statistical 
software package (version 14, SPSS Inc., Chicago, IL).
RESULTS
Baseline HRQOL Scores
Details of the baseline HRQOL scores are summarized 
in Table 2. Lowest baseline functional scores (indicating 
poorer functioning) were observed for global QoL (62.9 ± 1.1 
[SE of mean]), PF (61.8 ± 1.1), and role functioning (63.5 ± 
1.5). The highest baseline symptom scores (indicating 
more severe symptoms) were observed for dyspnea (47.1 
± 1.7), fatigue (37.4 ± 1.3), and insomnia (21.1 ± 1.6). For 
comparison purposes, Table 2 also includes normative data 
for the QLQ-C30 for the general Dutch population.21 As 66% 
of patients in our study were older than 70 years, normative 
data for both men and women aged 70 to 94 years have been 
used. As could be expected, all baseline functioning scales and 
several symptom scales including dyspnea were substantially 
poorer compared to those who were similarly aged in the gen-
eral population.
HRQOL Scores Over Time—Compliance Issues
The amount of HRQOL data available for analysis 
declined with increasing follow-up duration. Completed 
questionnaires were available for 76% (280 of 369), 62% 
(207 of 332), 59% (144 of 245), 36% (56 of 157), and 39% 
(43 of 110) of patients alive and without relapse at 3, 6, 12, 
18, and 24 months, respectively. Missing follow-up HRQOL 
data were mainly because of drop-outs resulting from the fact 
that our center was one of the few centers performing SABR, 
and many patients had been referred from other regions of 
the Netherlands. It was our common policy to follow patients 
from other regions only through visits to their primary chest 
physicians and by telephone after 6 to 12 months. Although 
follow-up visits and collection of QOL data were not formally 
stopped after the detection of a recurrence, in clinical practice 
most patients were referred back to their pulmonary physicians 
for either treatment or palliative care. The number of available 
QOL forms after the detection of a recurrence was therefore 
limited. For logistical reasons, it was not possible to collect 
HRQOL data for these patients. Consequently, the largest pro-
portion of missing data can be regarded as missing-at-random. 
However, we also examined whether those patients lost to 
follow-up had poorer baseline HRQOL than those for whom 
follow-up data were available. For each follow-up assessment, 
TABLE 2.  Baseline HRQOL Scores in the SABR Population
Percentiles
Normative HRQOL Data 
Dutch Population  
≥70 Years
N (valid) Mean SE of Mean 25 50 (median) 75 Male Female
Physical functioning 382 61.7 1.1 46.7 60.0 80.0 84 78
Role functioning 382 63.5 1.5 33.3 66.7 83.3 84 81
Cognitive functioning 380 82.9 1.1 66.7 83.3 100 86 91
Emotional functioning 380 75.1 1.2 60.4 83.3 91.7 92 87
Social functioning 380 82.2 1.3 66.7 100 100 93 90
Global quality of life 379 62.9 1.1 50.0 66.7 83.3 86 73
Fatigue 382 37.4 1.3 22.2 33.3 55.6 19 23
Nausea and vomiting 382 5.5 0.7 0.0 0.0 0.0 1.1 6.1
Pain 382 16.4 1.3 0.0 0.0 33.3 17 25
Dyspnea 382 47.1 1.7 33.3 33.3 66.7 12 14
Insomnia 382 21.1 1.6 0.0 0.0 33.3 13 23
Appetite loss 382 16.1 1.4 0.0 0.0 33.3 2.7 6.5
Constipation 379 9.8 1.1 0.0 0.0 0.0 7.4 10
Diarrhea 379 5.5 0.8 0.0 0.0 0.0 4.7 4.2
Financial impact 380 9.6 1.1 0.0 0.0 0.0 1.7 5.5
Normative data for Dutch population aged ≥70 years are shown in the right columns for comparison.
HRQOL, health-related quality of life; CI, confidence interval.
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we compared the mean baseline PF score for patients with and 
without HRQOL follow-up data at that time point. Patients 
with available PF data at 3, 6, 12, 18, and 24 months had 
a mean baseline PF score that was 2.7 (p = 0.30), 3.9 (p = 
0.09), 7.4 (p = 0.002), 7.2 (p = 0.02), and 9.6 points (p = 
0.008), respectively, higher than the mean baseline PF score 
of  corresponding patients for whom questionnaires at those 
time points were not available. This indicates some degree of 
bias in the follow-up data. However, although the observed 
differences were statistically significant beyond the 12-month 
assessment, the magnitude of these differences was relatively 
modest (i.e., below the 10-point threshold, indicative of clini-
cally significant differences). We also calculated effect sizes 
for the difference in baseline PF scores for patients with or 
without HRQOL data at each follow-up assessment. These 
were 0.12 (3 months), 0.17 (6 months), 0.33 (12 months), 0.32 
(18 months), and 0.43 (24 months), reflecting small effect 
sizes up to 18 months, and a moderate effect size at 24 months.
HRQOL Changes Over Time
The results of the multilevel analyses indicated that only 
one HRQOL domain assessed by the QLQ-C30, PF, decreased 
significantly in the first 2 years after SABR (p < 0.01). The 
mean decrease in PF was 5.7 and 5.6 points at 18 months and 
24 months, respectively, and thus did not meet our criterion 
for a “clinically meaningful difference.”18,19 No other mean 
QLQ-C30 score changed significantly from baseline to fol-
low-up (Table 3).
The results obtained on the basis of the multilevel analy-
ses are also reflected in the proportion of patients showing a 
“clinically meaningful change” (i.e., improving or deteriorat-
ing ≥10 points) from baseline to follow-up (Fig. 1). Compared 
to baseline values, PF at 1 year after SABR (n = 144) had 
decreased more than 10 points in 26%, had remained stable in 
53%, and had improved in 22% of patients. The comparative 
figures at 2-year post-SABR were 47% with decreased, 47% 
with stable, and 7% with improved PF scores; however, only a 
limited data were available with follow-up after 1 year.
Clinical Outcome
The median OS was 40 months, with an overall 2-year 
survival percentage of 66%. Local-, regional-, and distant fail-
ure percentages at 2 years were 6%, 13%, and 22%, respec-
tively (Fig. 2). Clinician-reported early side effects after 
SABR were present in 38% of the patients. Early toxicities 
most commonly described in the medical records were fatigue 
(27%), nausea (6%), increased dyspnea (5%), cough (5%), 
and local chest-wall pain (4%). Early toxicity of RTOG grade 
3 or higher was reported in eight patients (2.1%), consisting of 
pneumonia, which could not be differentiated from radiation 
pneumonitis in seven patients, and chest pain in the remaining 
patient. The most common clinician-reported late side effect 
was RTOG grade 3 or higher chronic chest-wall pain in 14 
patients (4%). In four patients (1%), rib fractures developed 
at the high-dose region on the thoracic wall, between 1 and 2 
years after SABR in the absence of local tumor progression. 
Radiation pneumonitis of grade 3 or higher, requiring treat-
ment with steroids, was observed in nine patients (2%).
Variables Predicting OS
Multivariate analysis indicated that a number of vari-
ables were independent predictors of survival, including: 
the baseline QLQ-C30 PF score (hazard ratio [HR] 1.44, 
95% confidence interval [CI] 1.01–2.05; p = 0.045), per-
formance status score (HR 1.36. 95% CI 1.01–1.85; p = 
0.047), the comorbidity score (HR 1.23 95% CI 1.06–1.43; 
TABLE 3.  Multilevel Mixed-Effects Linear Regression for HRQOL Dimensions
Intercept 
(95% CI)
3 Months 
(95% CI)
6 Months 
(95% CI)
12 Months 
(95% CI)
18 Months 
(95% CI)
24 Months 
(95% CI)
Global QoL 62.4 (60.5, 64.2) −1.0 (−3.1, 1.3) −0.2 (−2.7, 2.3) −1.5 (−4.3, 1.4) −3.0 (−7.3, 1.3) −0.6 (−5.4, 4.2) NS
Physical 60.8 (58.7, 63.0) −0.9 (−2.7, 0.9) −1.1 (−3.1, 0.9) −2.3 (−4.7, 0.0) −5.7 (−9.1, −2.2) −5.6 (−9.5, −1.7) p < 0.01
Emotional 75.4 (73.2, 77.6) −0.6 (−2.8, 1.7) 0.5 (−1.9, 3.0) 2.3 (−0.5, 5.2) 3.0 (−1.2, 7.3) 0.3 (−4.5, 5.1) NS
Role 61.8 (59.0, 64.6) −2.5 (−5.6, 0.5) −3.8 (−7.2, −0.4) −0.9 (−4.8, 3.1) −5.1 (−11.0, 0.8) −5.7 (−12.3, 0.9) NS
Social 81.0 (78.8, 83.2) −2.6 (−5.2, 0.1) −1.5 (−4.5, 1.4) −1.0 (−4.4, 2.4) −3.4 (−8.5, 1.6) −3.8 (−9.5, 1.9) NS
Cognitive 82.7 (80.6, 84.8) 0.4 (−1.5, 2.3) −1.8 (−3.9, 0.3) 0.6 (−1.9, 3.1) −1.9 (−5.6, 1.7) −3.1 (−7.2, 1.1) NS
Dyspnea 48.3 (45.2, 51.3) 1.6 (−1.6, 4.8) 1.4 (−2.2, 5.0) 4.5 (0.3, 8.6) −0.1 (−6.3, 6.1) 2.4 (−4.6, 9.4) NS
Fatigue 37.5 (35.1, 39.9) 0.3 (−2.1, 2.8) −0.7 (−3.5, 2.0) −0.6 (−2.1, 2.6) 2.7 (−2.1, 7.4) 4.7 (−0.6, 10.1) NS
Sleep difficulty 21.6 (18.9, 24.4) 1.5 (−1.8, 4.8) 0.2 (−3.5, 3.9) −0.1 (−4.3, 4.2) 0.4 (−6.0, 6.7) 2.1 (−5.0, 9.2) NS
Pain 17.6 (15.4, 19.9) 0.9 (−1.9, 3.7) 2.9 (−0.2, 6.1) 2.0 (−1.6, 5.6) 4.8 (−0.5, 10.2) 4.9 (−1.1, 10.9) NS
Loss of appetite 15.5 (13.2, 17.8) −0.7 (−3.5, 2.1) −1.7 (−4.9, 1.4) −1.8 (−5.4, 1.8) 0.8 (−4.6, 6.1) −1.8 (−7.9, 4.2) NS
Constipation 10.5 (9.6, 12.5) 1.5 (−0.9, 3.9) 1.3 (−1.4, 3.9) 0.1 (−3.0, 3.2) 3.1 (−1.5, 7.7) 0.6 (−4.4, 5.8) NS
Financial impact 9.3 (7.4, 11.2) −1.1 (−3.6, 1.4) −1.1 (−3.9, 1.7) 1.3 (−2.0, 4.5) 0.0 (−4.8, 4.8) 0.0 (−5.4, 5.4) NS
Diarrhea 6.1 (4.7, 7.5) 0.6 (−1.5, 2.8) 1.1 (−1.3, 3.5) 0.9 (−1.8, 3.7) 3.8 (−0.3, 7.9) 0.6 (−4.0, 5.2) NS
Nausea/vomiting 5.8 (4.5, 7.0) 0.8 (−0.8, 2.4) 0.4 (−1.4, 2.2) −0.7 (−2.8, 1.4) 1.5 (−1.6, 4.6) −0.1 (−3.6, 3.4) NS
HRQOL, health-related quality of life; CI, confidence interval; NS, not significant.
a p values indicate significance for the complete linear regression over time.
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p = 0.008), and baseline lung function expressed as absolute 
forced expiratory volume in 1 second (HR 1.07, 95% CI 
1.01–1.13; p = 0.027). Global HRQOL was not predictive 
of OS (p = 0.37).
DISCUSSION
Many elderly patients with early-stage NSCLC are 
undertreated, in part because of concerns about the deleteri-
ous effect of treatment on HRQOL.22–24 The introduction of 
SABR as an outpatient treatment delivered in three to eight 
fractions in less than 2 weeks, allows even frail patients to 
undergo curative treatment. A population-based time-trend 
registry study in the Netherlands revealed that the percentage 
of untreated patients aged 75 years and more, with a stage I 
NSCLC, decreased from 38% in the pre-SABR era to 28% 
after the introduction of SABR.24 Our finding of a 94% local 
control rate at 2 years and low incidence of late toxicity in 
this SABR patient population is in agreement with previous 
literature, and confirms the high efficacy and tolerability of 
this treatment approach.7–10
FIGURE 1.  Proportion of patients showing a clinically meaningful change (i.e., improving [green] or deteriorating [red] ≥10 
points) in HRQOL subscales at different time points, all with reference to their own baseline scores. HRQOL, health-related qual-
ity of life.
FIGURE 2.  Overall survival (left upper panel), disease-free survival (right upper panel), local control (left lower panel), regional 
control (left middle panel), and distant control (right lower panel) in 382 patients treated with SABR for stage I NSCLC. SABR, 
stereotactic ablative radiotherapy; NSCLC, non–small-cell lung cancer.
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Studies of changes in HRQOL after surgery for patients 
with stage I NSCLC generally show significant deteriorations 
in the initial months postoperatively.6,25–30 Although some of 
these studies reported that most HRQOL domains returned to 
baseline values at 6 to 9 months postoperatively, most reported 
a sustained decline in PF, particularly in patients aged 70 years 
or more, or in those with poor baseline HRQOL.25–29 In con-
trast, information on patient-reported HRQOL in early-stage 
NSCLC treated with SABR is still very limited. To date, only 
two other studies, one, studying a small series of 39 patients 
and the other, a larger series with 202 patients treated with 
SABR, have been reported.30,31 The main finding of our study 
is in agreement with these series in that the HRQOL of early-
stage NSCLC patients treated with SABR does not seem to 
be negatively affected. We observed a mean decrease of 2 to 
3 points/year in self-reported PF (on a scale of 0–100), which 
is comparable to that reported by Widder et al.,31 and which is 
well below the level that is commonly regarded as “clinically 
meaningful.”18,19 None of the other HRQOL domains assessed, 
including a range of functional and symptom outcomes, 
showed a statistically significant and/or clinically meaningful 
worsening in the first 2 years after SABR. This finding is in 
agreement with the low incidence of SABR toxicity reported 
in this and other series. The relative stability in observed 
HRQOL scores over time is notable, particularly given the 
fact that many of the patients undergoing SABR are elderly, 
frail, have significant comorbidity, and report relatively poor 
baseline HRQOL.
Patient-reported baseline HRQOL subscales, particu-
larly the global HRQOL and PF domain scores, have been 
established as important predictors for survival in advanced 
lung cancer.32,33 Our study showed that baseline PF is a strong 
independent predictor of survival in early-stage NSCLC as 
well. The additional significant predictive value of other base-
line characteristics, including World Health Organization per-
formance status, Charlson comorbidity scores, and pulmonary 
function further emphasize the relevance of the patient’s base-
line health condition for survival.
As was seen in another study on HRQOL in lung can-
cer,34 the major limitation of this study is the decreasing avail-
ability of HRQOL data with increasing follow-up time. With 
local medical ethical committee approval, it is our departmen-
tal policy to routinely collect HRQOL data on a voluntary basis 
from patients treated with SABR. However, as collection of 
these data takes place in the outpatient clinic, the completeness 
of the data is highly dependent on the pattern and location of 
follow-up visits. As we had treated patients with SABR from 
68 referring hospitals in the Netherlands, patients with longer 
travel distances were commonly referred back to their local 
hospitals for follow-up after 12 months. Although these miss-
ing data may be considered to be missing-at-random, it is also 
likely that patients whose HRQOL had declined significantly 
were either unable or unwilling to complete questionnaires 
at follow-up. As 64% and 61% of patients, respectively, were 
unavailable for follow-up at 18 and 24 months after SABR, it 
is possible that patients who completed follow-up at our cen-
ter were less ill than those with missing data, creating a bias 
toward higher HRQOL scores. However, for the earlier time 
points, compliance was sufficiently high to conclude that there 
is no clinically meaningful decrease in HRQOL in patients 
with early-stage NSCLC during the first year after SABR.
In conclusion, SABR is a highly effective treatment for 
stage I NSCLC, with limited toxicity. In contrast to surgery, 
SABR does not lead to significant worsening of HRQOL in 
the first year after treatment.
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